Uwell Biopharma, Inc.

NT$24.35As of Sun 8 Nov 2026, 12:00 UTC
TPEx:7902Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE (26.77%)
Biological Products, Except Diagnostic Substances
Beta (5Y) —
PE TTM —
TSR TTM —
Mkt cap NT$4.885B
ROIC (17.24%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$30
22.92%
(64.73%)
Hold 11|3|2|8|11
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.36
0.40
0.40
0.42
(1.97%)
5.39%
8.51%
19.79%
RevenueNT$M
282.8
290.7
290.2
297.1
13.38%
11.87%
6.48%
11.21%
Peers (US$147.5M)
Cap (US$)
PE
222.5M
—
187.8M
—
145.8M
—
Capital
TTM
5Y
10Y
Leveragex
1.522
(0.893)
(0.762)
EBIT/Intx
0.854
0.124
0.130
Own earn%
(9.24)
(3.10)
(5.48)
Sh yield%
9.34
29.29
27.27
Owners
Insiders/Inst%
0.29
53.07
Short interest%
5.72
SBC / revenue%
4.31
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
5–9
$1 testx
—
Incr. ROIC%
4